Arch Biopartners adds LSALT peptide trial sites in U.S. kidney injury program
The TSXV-listed company's shares rose 3.53 per cent as it widened enrollment capacity for its acute kidney injury candidate.
PR
By Priya Raman · Science Reporter
Oct 22 07:38 ETSource: kalkine.ca
The wire
- 01Arch Biopartners said its LSALT peptide program has added trial sites and expanded into the United States, broadening the kidney injury study footprint.
- 02Site expansion is the main lever on enrollment pace for a small-cap peptide developer, so it signals the program is still moving toward a readout.
- 03The item is framed around a single day's share move and gives no enrollment totals, timelines or interim data; nothing has been reported on efficacy.
From the source
Read at kalkine.caArch Biopartners Inc. (TSXV:ARCH) Gains 3.53% as LSALT Peptide Trial Sites Multiply and a U.S. Expansion Widens the Kidney Injury Programme
